We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Futura Medical Plc | LSE:FUM | London | Ordinary Share | GB0033278473 | ORD 0.2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.10 | 3.34% | 34.00 | 34.05 | 34.65 | 34.60 | 32.70 | 33.00 | 581,736 | 16:35:10 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.85M | -0.0194 | -17.55 | 102.39M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/8/2022 08:34 | Given the viagra market is around £2.5 BILLION, and there revenue alone around £400 million globally. Doesn’t take much to do the potential numbers here | haveapunt1 | |
31/8/2022 08:30 | All im saying, is you can’t cherry pick certain elements. The market is massive. There are plenty more positives here. Webcast will be interesting. Then we have potential commercial deals in the US to think about | haveapunt1 | |
31/8/2022 08:28 | this is the whole statement Summary comparison of MED3000 versus tadalafil in FM71 Both MED3000 and tadalafil exceeded the minimal clinically important differences at all time points and for all ED severities however overall tadalafil showed a greater improvement in erectile function than MED3000. MED3000 achieved the FDA agreed criteria for proving a rapid onset of action at 10 minutes where patients noticed an erection whereas tadalafil did not achieve the agreed criteria. MED3000 also showed a more favourable side effect profile compared to tadalafil. I do think J777 is right to point it out, but let's put it in perspective...He's always been very positive on FUM and trust him. | keifer derrin | |
31/8/2022 08:26 | J777 your being selective. It’s all there in the RNS. Your cherry picking. | haveapunt1 | |
31/8/2022 08:26 | Anyone reading LiarBO's posts yesterday might have been taken in by his carefully worded answers about whether he has a holding here. At no time has he said 'I am a holder', and for once, he has actually avoided lying by saying ' I have been a long term investor'. This bears out what I've been saying previously - that he was an LTH (not in dispute) but sold out 5 years ago when CSD500 failed with a huge loss. So it's a double whammy for LiarBO today - not only has the FDA agreed with everything that I and all the other 'rampers' have been saying and proved him totally wrong, but also he hasn't made any money on today's rise. I think he deserves a bit of respect for his troubles and we should spare a moment to think about his misfortune -bwahahahahahahahaha | petroc | |
31/8/2022 08:26 | You just have to look at the size of some of the buys to give you an indication where this is heading and there confidence. Anyone seen LBO this morning ????? ;-) | haveapunt1 | |
31/8/2022 08:25 | "however overall tadalafil showed a greater improvement in erectile function than MED3000." Futura's words not mine | j777j | |
31/8/2022 08:24 | MED3000 achieved the FDA agreed criteria for proving a rapid onset of action at 10 minutes where patients noticed an erection whereas tadalafil did not achieve the agreed criteria. MED3000 also showed a more favourable side effect profile compared to tadalafil. As I say. Isolation | haveapunt1 | |
31/8/2022 08:24 | Not many shares to buy during recession time. But this erectile dysfunction gel....it will sell like hot cakes regardless of recession! LOL Will be massive as viagra first launch. Still way undervalued. | deanmatlazin | |
31/8/2022 08:23 | Incorrect, your taking one element in isolation. It did not perform better on everything if you look at the results. Your also missing the point that this is the only OTC product. That is a HUGE benefit. MED3000 is in a very small handful of drugs available for ED. You can’t simply make isolated comparisons, no more than anyone does with viagra vs others in the marketplace | haveapunt1 | |
31/8/2022 08:22 | "however overall tadalafil showed a greater improvement in erectile function than MED3000." Just be careful | j777j | |
31/8/2022 08:20 | Very positive. The FDA were concerned that the benefit would reduce with future use. The fact that a greater benefit was shown at 24 weeks compared to the 12 weeks is impressive. And it seems they should be able to claim the 10 minute effect on marketing material. The only OTC treatment in the US in 2023 :) | pdt | |
31/8/2022 08:19 | As we all know there are many different interpretations of results Just be careful Fum also pointed out that the Cialis performed better overall! | j777j | |
31/8/2022 08:18 | J777 why would the FDA not lol. It’s a clinical trial (unless it was fudged). You can really fudge it. The FDA will run with the results from the trial. It was also run, agreed and planned with FDA input before hand | haveapunt1 | |
31/8/2022 08:16 | Anyone looking at the female version of this take a look at OVB. Mcap £8mil, about to launch and now commenced US and EU clinical trials. Fully funded. Directors hold 60% of shares, only 8mil in issue | haveapunt1 | |
31/8/2022 08:15 | Just be careful out there First and foremost we have to wait and see whether the FDA actually agrees with Fum's findings. This is Fum's findings not the FDA'S | j777j | |
31/8/2022 08:14 | Some trading going in at opens is my guess. Should hopefully consolidate now around 50p pending launch or approval with FDA | haveapunt1 | |
31/8/2022 08:14 | "notably med3000 helps men achieve first signs of an erection within 10 minutes." First signs is not an erection!!! Just a little uncertain what that actually means. | j777j | |
31/8/2022 08:09 | Big gap up. I'll wait till it gets filled | letmepass | |
31/8/2022 08:04 | 50p at open I reckon | losses | |
31/8/2022 07:52 | Hopefully a sustained rise after the first 10min ;-) | haveapunt1 | |
31/8/2022 07:47 | Sorry to hear you suffer with it | mikeh30 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions